|
1
|
Dang CV: Rethinking the Warburg effect
with Myc micromanaging glutamine metabolism. Cancer Res.
70:859–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sarker A, Im HJ, Cheon GJ, Chung HH, Kang
KW, Chung JK, Kim EE and Lee DS: Prognostic implications of the
SUVmax of primary tumors and metastatic lymph node measured by
18F-FDG PET in patients with uterine cervical cancer: a
meta-analysis. Clin Nucl Med. 41:34–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yamamoto M, Tsujikawa T, Fujita Y, Chino
Y, Kurokawa T, Kiyono Y, Okazawa H and Yoshida Y: Metabolic tumor
burden predicts prognosis of ovarian cancer patients who receive
platinum-based adjuvant chemotherapy. Cancer Sci. 107:478–485.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim C, Chung HH, Oh SW, Kang KW, Chung JK
and Lee DS: Differential diagnosis of borderline ovarian tumors
from stage I malignant ovarian tumors using FDG PET/CT. Nucl Med
Mol Imaging. 47:81–88. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Konishi H, Takehara K, Kojima A, Okame S,
Yamamoto Y, Shiroyama Y, Yokoyama T, Nogawa T and Sugawara Y:
Maximum standardized uptake value of fluorodeoxyglucose positron
emission tomography/computed tomography is a prognostic factor in
ovarian clear cell adenocarcinoma. Int J Gynecol Cancer.
24:1190–1194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chung HH, Kwon HW, Kang KW, Park NH, Song
YS, Chung JK, Kang SB and Kim JW: Prognostic value of preoperative
metabolic tumor volume and total lesion glycolysis in patients with
epithelial ovarian cancer. Ann Surg Oncol. 19:1966–1972. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Risum S, Loft A, Engelholm SA, Høgdall E,
Berthelsen AK, Nedergaard L, Lundvall L and Høgdall C: Positron
emission tomography/computed tomography predictors of overall
survival in stage IIIC/IV ovarian cancer. Int J Gynecol Cancer.
22:1163–1169. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto Y, Oguri H, Yamada R, Maeda N,
Kohsaki S and Fukaya T: Preoperative evaluation of pelvic masses
with combined 18F-fluorodeoxyglucose positron emission tomography
and computed tomography. Int J Gynaecol Obstet. 102:124–127. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jin L, Alesi GN and Kang S: Glutaminolysis
as a target for cancer therapy. Oncogene. 35:3619–3625. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tanizaki Y, Kobayashi A, Shiro M, Ota N,
Takano R, Mabuchi Y, Yagi S, Minami S, Terada M and Ino K:
Diagnostic value of preoperative SUVmax on FDG-PET/CT for the
detection of ovarian cancer. Int J Gynecol Cancer. 24:454–460.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sato M, Kawana K, Adachi K, Fujimoto A,
Yoshida M, Nakamura H, Nishida H, Inoue T, Taguchi A, Takahashi J,
et al: Spheroid cancer stem cells display reprogrammed metabolism
and obtain energy by actively running the tricarboxylic acid (TCA)
cycle. Oncotarget. 7:33297–33305. 2016.PubMed/NCBI
|
|
12
|
Kadoya T, Aogi K, Kiyoto S, Masumoto N,
Sugawara Y and Okada M: Role of maximum standardized uptake value
in fluorodeoxyglucose positron emission tomography/computed
tomography predicts malignancy grade and prognosis of operable
breast cancer: a multi-institute study. Breast Cancer Res Treat.
141:269–275. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park JC, Lee JH, Cheoi K, Chung H, Yun MJ,
Lee H, Shin SK, Lee SK and Lee YC: Predictive value of pretreatment
metabolic activity measured by fluorodeoxyglucose positron emission
tomography in patients with metastatic advanced gastric cancer: the
maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med
Mol Imaging. 39:1107–1116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kashiyama T, Oda K, Ikeda Y, Shiose Y,
Hirota Y, Inaba K, Makii C, Kurikawa R, Miyasaka A, Koso T, et al:
Antitumor activity and induction of TP53-dependent apoptosis toward
ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor
DS-7423. PLoS One. 9:e872202014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Keyes JW Jr: SUV: standard uptake or silly
useless value? J Nucl Med. 36:1836–1839. 1995.PubMed/NCBI
|
|
16
|
Mizuno T, Suzuki N, Makino H, Furui T,
Morii E, Aoki H, Kunisada T, Yano M, Kuji S, Hirashima Y, et al:
Cancer stem-like cells of ovarian clear cell carcinoma are enriched
in the ALDH-high population associated with an accelerated
scavenging system in reactive oxygen species. Gynecol Oncol.
137:299–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tjhay F, Motohara T, Tayama S, Narantuya
D, Fujimoto K, Guo J, Sakaguchi I, Honda R, Tashiro H and Katabuchi
H: CD44 variant 6 is correlated with peritoneal dissemination and
poor prognosis in patients with advanced epithelial ovarian cancer.
Cancer Sci. 106:1421–1428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kishton RJ, Barnes CE, Nichols AG, Cohen
S, Gerriets VA, Siska PJ, Macintyre AN, Goraksha-Hicks P, De Cubas
AA, Liu T, et al: AMPK is essential to balance glycolysis and
mitochondrial metabolism to control T-ALL cell stress and survival.
Cell Metab. 23:649–662. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Horsager J, Bak-Fredslund K, Larsen LP,
Villadsen GE, Bogsrud TV and Sørensen M: Optimal
2-[(18)F]fluoro-2-deoxy-D-galactose PET/CT protocol for detection
of hepatocellular carcinoma. EJNMMI Res. 6:562016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shida M, Murakami M, Tsukada H, Ishiguro
Y, Kikuchi K, Yamashita E, Kajiwara H, Yasuda M and Ide M: F-18
fluorodeoxyglucose uptake in leiomyomatous uterus. Int J Gynecol
Cancer. 17:285–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lutz AM, Ray P, Willmann JK, Drescher C
and Gambhir SS: 2-Deoxy-2-[F-18]fluoro-D-glucose accumulation in
ovarian carcinoma cell lines. Mol Imaging Biol. 9:260–266. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fan X, Ross DD, Arakawa H, Ganapathy V,
Tamai I and Nakanishi T: Impact of system L amino acid transporter
1 (LAT1) on proliferation of human ovarian cancer cells: a possible
target for combination therapy with anti-proliferative
aminopeptidase inhibitors. Biochem Pharmacol. 80:811–818. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kaira K, Nakamura K, Hirakawa T, Imai H,
Tominaga H, Oriuchi N, Nagamori S, Kanai Y, Tsukamoto N, Oyama T,
et al: Prognostic significance of L-type amino acid transporter 1
(LAT1) expression in patients with ovarian tumors. Am J Transl Res.
7:1161–1171. 2015.PubMed/NCBI
|
|
24
|
Lamkin DM, Spitz DR, Shahzad MM, Zimmerman
B, Lenihan DJ, Degeest K, Lubaroff DM, Shinn EH, Sood AK and
Lutgendorf SK: Glucose as a prognostic factor in ovarian carcinoma.
Cancer. 115:1021–1027. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saito Y, Chapple RH, Lin A, Kitano A and
Nakada D: AMPK protects leukemia-initiating cells in myeloid
leukemias from metabolic stress in the bone marrow. Cell Stem Cell.
17:585–596. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Venneti S, Dunphy MP, Zhang H, Pitter KL,
Zanzonico P, Campos C, Carlin SD, La Rocca G, Lyashchenko S,
Ploessl K, et al: Glutamine-based PET imaging facilitates enhanced
metabolic evaluation of gliomas in vivo. Sci Transl Med.
7:274ra172015. View Article : Google Scholar : PubMed/NCBI
|
